高崎総合医療センター英文論文一覧（2022）#心臓 #循環器系 #ランダム化比較試験 #多施設共同研究

心毒性の可能性があるがん治療に対するひずみ誘導管理による心保護 SUCCOUR 試
験の 3 年結果についての論文
Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki
S, Shirazi M, Santoro C, Cho GY, Popescu BA, Kosmala W, Costello B, laGerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa
K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E,
Banchs J, Kutty S, Negishi K, Marwick TH
Cardioprotection Using Strain-Guided Management of Potentially
Cardiotoxic Cancer Therapy 3-Year Results of the SUCCOUR Trial
JACC-Cardiovasc Imag. 2023 MAR;16(3):269-278.
Journal Impact Factor 2021: 16.051

PMID: 36435732 DOI: 10.1016/j.jcmg.2022.10.010 WoS: WOS:00104006390
0001#外科学 #症例報告

自家乳房再建後のブドウ球菌性トキシック・ショック症候群。症例報告および文献的考察についての論文
Nakamura H, Makiguchi T, Hasegawa Y, Yamatsu Y, Shoda K, Mori Y, Sakurai
K, Shirabe K, Yokoo S
Staphylococcal Toxic Shock Syndrome after Autologous Breast
Reconstruction: A Case Report and Literature Review
PRS-GLOB OPEN. 2022 DEC;10(12)Journal Impact Factor 2021: N/A

PMID: 36569240 DOI: 10.1097/GOX.0000000000004710 WoS: WOS:000920
338300004#腫瘍学 #多施設共同研究

高齢の進行性非小細胞肺がん患者における全身療法毒性の予測：国立病院機構による多施設共同前向き研究についての論文
Kanazu M, Shimokawa M, Saito R, Mori M, Tamura A, Okano Y, Fujita Y, Endo
T, Motegi M, Takata S, Kita T, Sukoh N, Takenoyama M, Atagi S

Predicting systemic therapy toxicity in older adult patients withadvanced non-small cell lung cancer: A prospective multicenter study of
National Hospital Organization in JapanJ Geriatr Oncol. 2022 NOV;13(8):1216-1222.
Journal Impact Factor 2021: 3.929

PMID: 36008273 DOI: 10.1016/j.jgo.2022.07.011 WoS: WOS:000966250700
018#腫瘍学 #ランダム化比較試験 #多施設共同研究

切除不能な肝細胞癌に対するアテゾリズマブ＋ベバシズマブとレンバチニブの比較：
世界の大規模実戦集団についての論文
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J,
Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F,
Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V,
Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki
T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M,
Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T,
Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka
T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A,
Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka
H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio
V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S,
Cucchetti A
Atezolizumab plus bevacizumab versus lenvatinib for unresectable
hepatocellular carcinoma: a large real-life worldwide population
Eur J Cancer. 2023 FEB;180:9-20.
Journal Impact Factor 2021: 10.002

PMID: 36527976 DOI: 10.1016/j.ejca.2022.11.017 WoS: WOS:00092823630
0001#消化器病学 #肝臓学

C 型慢性肝炎に対する直接作用型抗ウイルス療法後の予後と免疫学的および腫瘍学的合併症の発生率についての論文

Kanayama Y, Sato K, Saito S, Ueno T, Shimada Y, Kohga T, Shibasaki
M, Naganuma A, Takakusagi S, Nagashima T, Nakajima H, Takagi H, Uehara
D, Uraoka T
Prognosis and incidence of immunological and oncological complications
after direct-acting antiviral therapy for chronic hepatitis C
Acta Gastro-Enterol Belg. 2022 OCT-DEC;85(4):601-609.
Journal Impact Factor 2021: 1.692

PMID: 36566370 DOI: 10.51821/85.4.9925 WoS: WOS:000933828100001#消化器病学 #肝臓学 #多施設共同研究

転移・再発の膵腺扁平上皮癌患者に対する化学療法の有効性：多施設共同レトロスペ
クティブ解析による検討についての論文
Yoshida Y, Kobayashi S, Ueno M, Morizane C, Tsuji K, Maruki Y, Mori K,
Watanabe K, Ohba A, Furuta M, Todaka A, Tsujimoto A, Ozaka M, Okano N,
Yane K, Umemoto K, Kawamoto Y, Terashima T, Tsumura H, Doi K, Shioji K,
Asagi A, Kojima Y, Suzuki E, Toshiyama R, Furukawa M, Naganuma
A, Suzuki R, Miwa H, Ikeda M, Furuse J
Efficacy of chemotherapy for patients with metastatic or recurrent
pancreatic adenosquamous carcinoma: A multicenter retrospective
analysis
Pancreatology. 2022 DEC;22(8):1159-1166.
Journal Impact Factor 2021: 3.977

PMID: 36150984 DOI: 10.1016/j.pan.2022.09.236 WoS: WOS:000920796100
013
#腫瘍学

肝細胞癌患者におけるアテゾリズマブとベバシズマブまたはレンバチニブの併用による臨床転帰：多施設実地試験についての論文
Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J,
Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F,
Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V,
Pressiani T, Kawaguchi T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A,
Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F,
Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M,
Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji
K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T,

Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K,
Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka
H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y,
Cammarota A, Burgio V, Cascinu S, Casadei-Gardini A
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib inpatients with hepatocellular carcinoma: a multicenter real-world study
J Cancer Res Clin Oncol. 2023 AUG;149(9):5591-5602.
Journal Impact Factor 2021: 4.322

PMID: 36509984 DOI: 10.1007/s00432-022-045121 WoS: WOS:000905268700001#腫瘍学

アテゾリズマブとベバシズマブの併用療法を受けた切除不能な肝細胞癌患者における治療効果の潜在的な予測因子としての有害事象についての論文
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A,
Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y
Adverse events as potential predictive factors of therapeutic activity inpatients with unresectable hepatocellular carcinoma treated withatezolizumab plus bevacizumab
Cancer Med. 2023 APR;12(7):7772-7783.
Journal Impact Factor 2021: 4.711

PMID: 36518086 DOI: 10.1002/cam4.5535 WoS: WOS:000904953700001#腫瘍学

アテゾリズマブ＋ベバシズマブによる治療を受けた切除不能進行肝細胞癌患者において、炎症と肝機能に基づく新しい予後予測システム。検証試験についての論文
Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K,
Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T,
Yasuda S, Ogawa C, Toyoda H, Hatanaka T, Nishimura T, Kakizaki S, Kawata
K, Shimada N, Tada F, Nouso K, Tsutsui A, Ohama H, Morishita A, Nagano T,
Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S,
Koizumi Y, Kaibori M, Iijima H, Hiasa Y

New prognostic system based on inflammation and liver function
predicts prognosis in patients with advanced unresectable
hepatocellular carcinoma treated with atezolizumab plus bevacizumab:
A validation study
Cancer Med. 2023 MAR;12(6):6980-6993.
Journal Impact Factor 2021: 4.711

PMID: 36484470 DOI: 10.1002/cam4.5495 WoS: WOS:000905037900001#心臓 #循環器系 #多施設共同研究

血行動態に関連した冠動脈疾患検出のための動的ストレス CT 灌流イメージングのフラクタル解析についての論文
Michallek F, Nakamura S, Kurita T, Ota H, Nishimiya K, Ogawa R, Shizuka T,
Nakashima H, Wang YN, Ito T, Sakuma H, Dewey M, Kitagawa K
Fractal Analysis of Dynamic Stress CT-Perfusion Imaging for Detectionof Hemodynamically Relevant Coronary Artery Disease
JACC-Cardiovasc Imag. 2022 SEP;15(9):1591-1601.
Journal Impact Factor 2021: 16.051

PMID: 36075619 DOI: 10.1016/j.jcmg.2022.03.015 WoS: WOS:00089847730
0008
#腫瘍学

アテゾリズマブ＋ベバシズマブによる治療を受けた進行切除不能肝細胞癌患者における栄養状態は予後と関連することについての論文
Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K,
Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T,
Yasuda S, Ogawa C, Toyoda H, Hatanaka T, Nishimura T, Kakizaki S, Kawata
K, Shimada N, Tada F, Nouso K, Tsutsui A, Ohama H, Morishita A, Nagano T,
Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S,
Koizumi Y, Matono T, Kaibori M, Iijima H, Hiasa Y, Real-Life Practice Experts
HCC REL, Hepatocellular Carcinoma Experts 4
Nutritional status is associated with prognosis in patients with advanced
unresectable hepatocellular carcinoma treated with atezolizumab plus
bevacizumab
Oncology. 2023 APR;101(4):270-281.
Journal Impact Factor 2021: 3.734

PMID: 36455517 DOI: 10.1159/000527676 WoS: WOS:000894866900001

#腫瘍学

切除不能肝細胞癌患者におけるアテゾリズマブ＋ベバシズマブ併用療法と筋量減少の関係-多施設共同解析についての論文
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Naganuma A, Kaibori M, Tanaka T, Ohama H, Nouso
K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M,
Koizumi Y, Nakamura S, Joko K, Iijima H, Kosaka H, Hiasa Y, Kudo M
Relationship of atezolizumab plus bevacizumab treatment with muscle
volume loss in unresectable hepatocellular carcinoma patientsmulticenter analysis
Liver Cancer. 2023 AUG;12(3):209-217.
Journal Impact Factor 2021: 12.43

PMID: 37601983 DOI: 10.1159/000527402 WoS: WOS:000898237400001#腫瘍学

非ウイルス性切除不能肝細胞癌におけるアテゾリズマブとベバシズマブの併用療法とレンバチニブとソラフェニブの併用療法：国際的な傾向スコアマッチング解析についての論文
Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C,
Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra
F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M,
Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F,
Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M,
Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji
K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T,
Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K,
Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai
M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F,
De Cobelli F, Ratti F, Alrighetti L, Kudo M, Cascinu S, Casadei-Gardini A
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in nonviral unresectable hepatocellular carcinoma: an international propensity
score matching analysis
ESMO Open. 2022 DEC;7(6)Journal Impact Factor 2021: 6.883

PMID: 36208496 DOI: 10.1016/j.esmoop.2022.100591 WoS: WOS:00089070
8000001#医学 #一般医療 #内科学 #多施設共同研究

SARS-CoV-2 感染症患者に対する Favipiravir の有効性及び安全性の評価。多施設
共同非無作為化単群前向き試験についての論文
Yanagisawa K, Takara K, Suga H, Saito A, Hayashi T, Igarashi T, Tomizawa
S, Saito E, Sumiyoshi H, Ohyama Y, Tokue Y, Nakamura T
The Assessment of the Efficacy and Safety of Favipiravir for Patientswith SARS-CoV-2 Infection: A Multicenter Non-randomized,
Uncontrolled Single-arm Prospective Study
Intern Med. 2022;61(21):3197-3204.
Journal Impact Factor 2021: 1.282

PMID: 35945028 DOI: 10.2169/internalmedicine.969122 WoS: WOS:000893262400001#腫瘍学

切除不能進行性膵臓がんに対するナノリポソームイリノテカンと 5-フルオロウラシル／ロイコボリン併用療法の有効性と安全性に関するリアルワールドスタディについての論文
Yasuoka H, Naganuma A, Kurihara E, Kobatake T, Ijima M, Tamura
Y, Suzuki Y, Hoshino T, Ishida F, Hosaka H, Hatanaka T, Yoshida S, Aihara
R, Hosouchi Y, Ishii N, Araki K, Shirabe K, Uraoka T, Kakizaki S
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan
and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic
Cancer: A Real-World Study
Oncology. 2022;100(8):449-459.
Journal Impact Factor 2021: 3.734

PMID: 35816996 DOI: 10.1159/000525742 WoS: WOS:000889465500004#麻酔学

好塩基球活性化試験で示された免疫グロブリン E 依存性機序を示唆する術中クロルヘ
キシジン誘発アナフィラキシー：2 症例報告についての論文
Orihara M, Takazawa T, Horiuchi T, Nagumo K, Maruyama N, Tomioka A,
Saito SIntraoperative chlorhexidine-induced anaphylaxis suggesting an
immunoglobulin-E-dependent mechanism indicated by basophil
activation tests: two case reports
JA CLIN REP. 2022 NOV 22;8(1)Journal Impact Factor 2021: N/A

PMID: 36417006 DOI: 10.1186/s40981-022-00581w WoS: WOS:000886998000002#外科学

先天性第 V 因子欠乏症患者における肝細胞癌に対する腹腔鏡下肝切除術：症例報告についての論文Seki T, Tsukagoshi M, Harimoto N, Araki K, Watanabe A, Ishii N, Hagiwara K,
Hoshino K, Muranushi R, Kakizaki S, Ogawa Y, Handa H, Shirabe K
Laparoscopic hepatectomy for hepatocellular carcinoma in a patientwith congenital factor V deficiency: a case report
SURG CASE REP. 2022 OCT 22;8(1)Journal Impact Factor 2021: N/A

PMID: 36271957 DOI: 10.1186/s40792-022-015597 WoS: WOS:000871189100002#腫瘍学

切除不能な肝細胞癌に対するアテゾリズマブ＋ベバシズマブ併用療法に伴う有害事象
としての尿蛋白の臨床的予測因子についての論文
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Tada F, Nouso K,
Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M,
Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M, Real-life
Practice Experts HCC REL
Clinical predictor of urinary protein as adverse event associated withatezolizumab plus bevacizumab treatment for unresectable
hepatocellular carcinoma
Oncology. 2022 SEP 14;
Journal Impact Factor 2021: 3.734

PMID: 36103846 DOI: 10.1159/000526521 WoS: WOS:000873782800001

#臨床神経学

日本人成人発症脳小血管障害患者における HTRA1 および ABCC6 変異の高頻度発現についての論文
Uemura M, Hatano Y, Nozaki H, Ando S, Kondo H, Hanazono A, Iwanaga A,
Murota H, Osakada Y, Osaki M, Kanazawa M, Kanai M, Shibata Y, Saika R,
Miyatake T, Aizawa H, Ikeuchi T, Tomimoto H, Mizuta I, Mizuno T, Ishihara T,
Onodera O
High frequency of HTRA1 AND ABCC6 mutations in Japanese patientswith adult-onset cerebral small vessel disease
J Neurol Neurosurg Psychiatry. 2023 JAN;94(1):74-81.
Journal Impact Factor 2021: 13.654

PMID: 36261288 DOI: 10.1136/jnnp-2022329917 WoS: WOS:000870714400001#ナノ科学 #ナノテクノロジ #第 II 相試験 #多施設共同研究 #ランダム化比較試験

進行・再発乳がんを対象とした NK105 とパクリタキセルの治療成績を比較する多施設共同無作為化非盲検第 II 相臨床試験についての論文
Kosaka Y, Saeki T, Takano T, Aruga T, Yamashita T, Masuda N, Koibuchi Y,
Osaki A, Watanabe J, Suzuki R
Multicenter Randomized Open-Label Phase II Clinical Study Comparing
Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast
Cancer
Int J Nanomed. 2022;17:4567-4578.
Journal Impact Factor 2021: 7.033

PMID: 36217496 DOI: 10.2147/IJN.S372477 WoS: WOS:000870533400001#腫瘍学

アテゾリズマブとベバシズマブの有効性と安全性をウイルス感染と非ウイルス感染の肝細胞癌患者で比較した。日本の多施設共同観察研究についての論文
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T,
Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N,
Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y,
Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T

Comparative efficacy and safety of atezolizumab and bevacizumab
between hepatocellular carcinoma patients with viral and non-viral
infection: A Japanese multicenter observational study
Cancer Med. 2023 MAR;12(5):5293-5303.
Journal Impact Factor 2021: 4.711

PMID: 36226511 DOI: 10.1002/cam4.5337 WoS: WOS:000866391000001#腫瘍学

アテゾリズマブとベバシズマブによる治療を受けた患者の新しい予後予測スコアとしての肝細胞癌 modified Gustave Roussy Immune スコア（HCC-GRIm スコア）。多施設共同レトロスペクティブ解析についての論文
Hatanaka T, Naganuma A, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T,
Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N,
Kawata K, Kosaka H, Kakizaki S, Tanaka T, Ohama H, Nouso K, Morishita A,
Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y,
Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T, Real-life Practice Experts
HCC REL, HCC 48 Grp Hepatocellular Carcinom
The hepatocellular carcinoma modified Gustave Roussy Immune score(HCC-GRIm score) as a novel prognostic score for patients treated withatezolizumab and bevacizumab: A multicenter retrospective analysis
Cancer Med. 2023 FEB;12(4):4259-4269.
Journal Impact Factor 2021: 4.711

PMID: 36156452 DOI: 10.1002/cam4.5294 WoS: WOS:000860249500001#微生物学

日本で採取された無症候性検体を用いた E 型肝炎ウイルス血清学的測定法のキャリブ
レーションについての論文
Terahara K, Li TC, Matsubayashi K, Sakata H, Kato T, Naganuma A, Ogawa
K, Honda K, Itakura J, Akutsu N, Tobita H, Korenaga M, Kanto T, Sugiyama R,
Suzuki R, Hamaguchi I, Isogawa M, Takahashi Y
Calibrating Hepatitis E Virus Serological Assays Using Asymptomatic
Specimens Obtained in Japan
Microbiol Spectr. 2022 SEP 20;
Journal Impact Factor 2021: 9.043

PMID: 36125314 DOI: 10.1128/spectrum.0214622 WoS: WOS:000855951000001#消化器病学 #肝臓学 #多施設共同研究

アテゾリズマブとベバシズマブ投与中の肝細胞癌患者に対する修正アルブミン-ビリル
ビン値およびα-フェトプロテイン値（mALF スコア）の開発と検証についての論文
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T,
Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N,
Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y,
Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T, Real-life Practice Experts
HCC REL, HCC 48 Grp Hepatocellular Carinoma
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients
receiving atezolizumab and bevacizumab
Hepatol Int. 2023 FEB;17(1):86-96.
Journal Impact Factor 2021: 9.046

PMID: 36076009 DOI: 10.1007/s12072-022-104068 WoS: WOS:000852263200001#公衆衛生学 #環境衛生学 #労働衛生学

子宮内膜がんサバイバーに採用された集中的サーベイランスの実施に関する再評価についての論文Nakamura K, Kitahara Y, Yamashita S, Kigure K, Ito I, Nishimura T, Azuma A,
Kanuma T
Reassessment of intensive surveillance practices adopted forendometrial cancer survivors
BMC Womens Health. 2022 AUG 23;22(1)Journal Impact Factor 2021: 2.742

PMID: 35999573 DOI: 10.1186/s12905-022-019371 WoS: WOS:000846692100001#腫瘍学 #観察研究

高齢者の切除不能膵臓癌におけるゲムシタビン＋Nab-Paclitaxel とゲムシタビン単独の有効性・安全性の比較検討についての論文

Kobayashi S, Suzuki M, Ueno M, Maruki Y, Okano N, Todaka A, Ozaka M, Tsuji
K, Shioji K, Doi K, Kojima Y, Tsumura H, Tanaka K, Higuchi H, Kawabe K,
Imaoka H, Yamashita T, Miwa H, Nagano H, Arima S, Hayashi H, Naganuma
A, Yamaguchi H, Hisano T, Umemoto K, Ishii S, Nakashima K, Suzuki R,
Kitano Y, Misumi T, Furuse J, Ishii H
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel
versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic
CancerOncologist. 2022 OCT 1;27(10):E774-E782.
Journal Impact Factor 2021: 5.837

PMID: 35946841 DOI: 10.1093/oncolo/oyac157 WoS: WOS:00083881230000
1#医学 #一般医療 #内科学 #症例報告

アテゾリズマブ＋ベバシズマブで治療した切除不能な肝細胞癌と胆管癌の複合体の一例についての論文
Saito N, Hatanaka T, Nakano S, Hazama Y, Yoshida S, Hachisu Y, Tanaka Y,
Yoshinaga T, Kashiwabara K, Norio K, Hosouchi Y, Tojima H, Kakizaki S,
Uraoka T
A case of unresectable combined hepatocellular and cholangiocarcinoma
treated with atezolizumab plus bevacizumab
Clin Case Rep. 2022 JUL;10(7)Journal Impact Factor 2021: N/A

PMID: 35898742 DOI: 10.1002/ccr3.6129 WoS: WOS:000830436000001#腫瘍学 #レビュー論文

進行性胃がんにおけるニボルマブの治療感度の強力な予後マーカーとしての Gustave
Roussy 免疫スコアの変化。多施設共同レトロスペクティブ研究についての論文
Nakazawa N, Sohda M, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka
H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sano A, Sakai M, Ogawa H,
Shirabe K, Saeki H
Changes in the Gustave Roussy Immune Score as a Powerful Prognostic
Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric
Cancer: A Multicenter, Retrospective StudyAnn Surg Oncol. 2022 NOV;29(12):7400-7406.
Journal Impact Factor 2021: 4.339

PMID: 35857197 DOI: 10.1245/s10434-022-122264 WoS: WOS:000827911900002#消化器病学 #肝臓学 #多施設共同研究

グラスゴー予後スコアはレンバチニブ治療を受けた切除不能な肝細胞癌患者の生存率を予測する：多施設共同解析についての論文
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka
T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T,
Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa
Y, Kudo M, Real Life Practice Experts HCC REL, Hepatocellular Carcinoma
Experts C
Glasgow prognostic score predicts survival in patients with unresectable
hepatocellular carcinoma treated with lenvatinib: a multicenter analysis
Eur J Gastroenterol Hepatol. 2022 AUG;34(8):857-864.
Journal Impact Factor 2021: 2.586

PMID: 35802527 DOI: 10.1097/MEG.0000000000002398 WoS: WOS:000822
069100007#消化器病学 #肝臓学

Lenvatinib 投与による肝細胞癌患者の予後因子としての血清アルブミンの経時的変化：modified albumin-bilirubin score（ALBS グレード）に基づくアルブミン簡
略化グレードの提案についての論文
Kariyama K, Hiraoka A, Kumada T, Yasuda S, Toyoda H, Tsuji K, Hatanaka
T, Kakizaki S, Naganuma A, Tada T, Takaguchi K, Itobayashi E, Ishikawa T,
Shimada N, Tsutsui A, Nagano T, Imai M, Nakamura S, Wakuta A, Miyake N,
Shiota S, Nouso K
Chronological change in serum albumin as a prognostic factor inpatients with hepatocellular carcinoma treated with lenvatinib: proposalof albumin simplified grading based on the modified albumin-bilirubinscore (ALBS grade)
J Gastroenterol. 2022 AUG;57(8):581-586.
Journal Impact Factor 2021: 6.772

PMID: 35763116 DOI: 10.1007/s00535-022-018837 WoS: WOS:000817841300001

#消化器病学 #肝臓学 #多施設共同研究

アテゾリズマブとベバシズマブの併用療法を受けた肝細胞癌患者における免疫療法ス
コアにおける CRP とα-フェトプロテインの予後への影響：多施設共同レトロスペク
ティブ研究についての論文
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T,
Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N,
Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y,
Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T, Real-life PracticeExperts HCC REL, HCC 48 Grp Hepatocellular Carcinom
Prognostic impact of C-reactive protein and alpha-fetoprotein in
immunotherapy score in hepatocellular carcinoma patients treated withatezolizumab plus bevacizumab: a multicenter retrospective study
Hepatol Int. 2022 OCT;16(5):1150-1160.
Journal Impact Factor 2021: 9.046

PMID: 35749019 DOI: 10.1007/s12072-022-10358z WoS: WOS:000815425400001#消化器病学 #肝臓学 #多施設共同研究

2000 年から 2020 年までのウイルス性肝細胞癌の生存率の向上と非ウイルス性肝細胞癌の生存率の向上。日本の大規模医療施設における 6007 例の多施設共同コホート研究についての論文
Toyoda H, Kariyama K, Hiraoka A, Tsuji K, Ishikawa T, Hatanaka
T, Naganuma A, Yasuda S, Nouso K, Kakizaki S, Kumada T, Innes H,
Johnson PJ
Improved survival of viral hepatocellular carcinoma but non-viral
hepatocellular carcinoma from 2000 to 2020: A multicenter cohort studyof 6007 patients from high-volume academic centers in Japan
Aliment Pharmacol Ther. 2022 AUG;56(4):694-701.
Journal Impact Factor 2021: 9.524

PMID: 35707936 DOI: 10.1111/apt.17088 WoS: WOS:000811476200001

#血液学

播種性血管内凝固症候群患者における血清 high mobility group box 1 protein お
よび histone H3 レベルの予後価値：多施設共同前向きコホート研究についての論文
Mori H, Kataoka Y, Harada-Shirado K, Kawano N, Hayakawa M, Seki
Y, Uchiyama T, Yamakawa K, Ishikura H, Irie Y, Nishio K, Yada N, Okamoto
K, Yamada S, Ikezoe T
Prognostic value of serum high mobility group box 1 protein and histone
H3 levels in patients with disseminated intravascular coagulation: amulticenter prospective cohort study
Thromb J. 2022 JUN 13;20(1)Journal Impact Factor 2021: 5.509

PMID: 35698137 DOI: 10.1186/s12959-022-003902 WoS: WOS:000810667000001#消化器病学 #肝臓学

実臨床における Child-Pugh クラス A または B の肝機能を有する切除不能な肝細胞癌に対するアテゾリズマブとベバシズマブの併用療法による治療効果についての論文
Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Nouso K, Morishita
A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y,
Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T, Real-life
Practice Experts HCC REL, HCC 48 Grp Hepatocellular Carcinom
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for
unresectable hepatocellular carcinoma in patients with Child-Pugh class
A or B liver function in real-world clinical practiceHepatol Res. 2022 SEP;52(9):773-783.
Journal Impact Factor 2021: 4.942

PMID: 35633504 DOI: 10.1111/hepr.13797 WoS: WOS:000809409900001#腫瘍学

切除不能な肝細胞癌に対する一次治療は予後に影響を与えるか -アテゾリズマブ＋ベ
バシズマブ併用療法とレンバチニブ併用療法の比較についての論文
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,

Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T,
Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T,
Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y,
Kudo M, Real-Life Practice Experts HCC REL, HCC 48 Grp Hepatocellular
Carcinom
Does first-line treatment have prognostic impact for unresectable HCC?Atezolizumab plus bevacizumab versus lenvatinib
Cancer Med. 2023 JAN;12(1):325-334.
Journal Impact Factor 2021: 4.711

PMID: 35666040 DOI: 10.1002/cam4.4854 WoS: WOS:000805673700001#複合科学

レンバチニブ治療を受けた切除不能な肝細胞癌患者における C 反応性タンパク質／アルブミン比は生存率を予測することについての論文
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka
T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T,
Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa
Y, Kudo M
C-reactive protein to albumin ratio predicts survival in patients withunresectable hepatocellular carcinoma treated with lenvatinib
Sci Rep. 2022 MAY 19;12(1)Journal Impact Factor 2021: 4.997

PMID: 35589772 DOI: 10.1038/s41598-022-12058y WoS: WOS:000798064600031#腫瘍学 #多施設共同研究

高齢者肝細胞癌患者の予後：日本における多施設共同 19 年間の経験についての論文
Hatanaka T, Kakizaki S, Hiraoka A, Kariyama K, Tsuji K, Ishikawa T, Toyoda
H, Yasuda S, Naganuma A, Tada T, Takaguchi K, Tsutsui A, Itobayashi E,
Shimada N, Shibata H, Tanaka T, Nagano T, Imai M, Nakamura S, Nouso K,
Kosaka H, Kaibori M, Kumada T, Real-life Practice Experts HCC REL
The prognosis of elderly patients with hepatocellular carcinoma: A
multi-center 19-year experience in Japan

Cancer Med. 2023 JAN;12(1):345-357.
Journal Impact Factor 2021: 4.711

PMID: 35608226 DOI: 10.1002/cam4.4850 WoS: WOS:000799252200001#老年医学 #老年学

日本人サルコペニア性嚥下障害データベースにおけるふくらはぎ周囲径と脳卒中は食事摂取レベルスケールの改善に対する独立した予測因子であったということについての論文
Kimura M, Naganuma A, Ogawa Y, Inagawa M, Nishioka S, Momosaki R,
Wakabayashi H
Calf circumference and stroke are independent predictors for an
improvement in the food intake level scale in the Japanese sarcopenic
dysphagia database
Eur Geriatr Med. 2022 OCT;13(5):1211-1220.
Journal Impact Factor 2021: 3.269

PMID: 35612760 DOI: 10.1007/s41999-022-006513 WoS: WOS:000800085800001#消化器病学 #肝臓学 #症例報告

副腎転移と血管浸潤を伴う巨大肝細胞癌に対してアテゾリズマブ-ベバシズマブ治療後に肝切除術に移行した 1 症例についての論文
Hoshino T, Naganuma A, Furusawa A, Suzuki Y, Hirai K, Sakamoto
I, Ogawa T, Ogawa A, Hatanaka T, Kakizaki S
A case of conversion hepatectomy for huge hepatocellular carcinoma
with adrenal metastasis and vascular invasion after atezolizumabbevacizumab treatment
Clin J Gastroenterol. 2022 AUG;15(4):776-783.
Journal Impact Factor 2021: N/A

PMID: 35585285 DOI: 10.1007/s12328-022-016442 WoS: WOS:000797289800001#消化器病学 #肝臓学 #多施設共同研究

アテゾリズマブとベバシズマブの併用療法を受けた切除不能な肝細胞癌患者における好中球・リンパ球比率は早期転帰を予測する：多施設共同解析についての論文
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,

Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y,
Nakamura S, Joko K, Iijima H, Hiasa Y, Reallife Practice Experts HCC REL,
Hepatocellular Carcinoma Experts 4
Neutrophil-lymphocyte ratio predicts early outcomes in patients withunresectable hepatocellular carcinoma treated with atezolizumab plus
bevacizumab: a multicenter analysis
Eur J Gastroenterol Hepatol. 2022 JUN;34(6):698-706.
Journal Impact Factor 2021: 2.586

PMID: 35170529 DOI: 10.1097/MEG.0000000000002356 WoS: WOS:000788
209200015#複合科学 #多施設共同研究

4D Dynamic Myocardial Stress-CT perfusion imaging のフラクタル解析による多施設共同実証試験における微小血管虚血と大血管虚血の鑑別効果についての論文
Michallek F, Nakamura S, Ota H, Ogawa R, Shizuka T, Nakashima H, Wang
YN, Ito T, Sakuma H, Dewey M, Kitagawa K
Fractal analysis of 4D dynamic myocardial stress-CT perfusion imaging
differentiates micro- and macrovascular ischemia in a multi-center
proof-of-concept study
Sci Rep. 2022 MAR 24;12(1)Journal Impact Factor 2021: 4.997

PMID: 35332236 DOI: 10.1038/s41598-022-091446 WoS: WOS:000773009200053#腫瘍学 #多施設共同研究

高齢者肝細胞癌患者に対するアテゾリズマブとベバシズマブの併用療法の安全性と有効性：多施設共同解析結果についての論文
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y,
Nakamura S, Joko K, Iijima H, Hiasa Y, Real-life Practice Experts HCC REL,
Hepatocellular Carcinoma Experts 4

Safety and efficacy of atezolizumab plus bevacizumab in elderly patientswith hepatocellular carcinoma: A multicenter analysis
Cancer Med. 2022 OCT;11(20):3796-3808.
Journal Impact Factor 2021: 4.711

PMID: 35441477 DOI: 10.1002/cam4.4763 WoS: WOS:000783714100001#外科学

COVID-19 流行時の群馬県内の 17 のがん診療連携拠点病院における胃がん、大腸がん、肺がん、乳がんの手術件数の減少についての論文
Saeki H, Shirabe K, Miyazaki T, Ogawa T, Makita F, Shitara Y, Machida M,
Yasuda N, Kato H, Ojima H, Hosouchi Y, Naito H, Tatsuki H, Uchida N,
Iwanami K, Kohri T, Hayashi K, Iwasaki S, Koyama H
Decreased numbers of gastric, colorectal, lung, and breast cancer
surgeries performed in 17 cancer-designated hospitals in Gunma
Prefecture of Japan during the COVID-19 pandemic
Surg Today. 2022 DEC;52(12):1714-1720.
Journal Impact Factor 2021: 2.54

PMID: 35426582 DOI: 10.1007/s00595-022-02501y WoS: WOS:000782726200001#医学 #一般医療 #内科学 #症例報告

青年期の C 型慢性肝炎は、直接作用型抗ウイルス療法の良い候補になるかもしれない
ことについての論文
Sato K, Yamazaki Y, Kanayama Y, Uehara D, Tojima H, Suga T, Kakizaki S,
Sohara N, Horiguchi N, Uraoka T
Adolescents with chronic hepatitis C might be good candidates for
direct-acting antiviral therapy
Clin Case Rep. 2022 APR;10(4)Journal Impact Factor 2021: N/A

PMID: 35414915 DOI: 10.1002/ccr3.5690 WoS: WOS:000777972100001#医学 #一般医療 #内科学

デジタルブレストトモシンセシスにおける画質向上と被ばく低減を目的としたGenerative Adversarial Network の評価についての論文
Gomi T, Kijima Y, Kobayashi T, Koibuchi Y

Evaluation of a Generative Adversarial Network to Improve Image
Quality and Reduce Radiation-Dose during Digital Breast Tomosynthesis
Diagnostics. 2022 FEB;12(2)Journal Impact Factor 2021: 3.992

PMID: 35204582 DOI: 10.3390/diagnostics12020495 WoS: WOS:0007708925
00001
#生物学

I-II 期の非膨大型子宮頸部扁平上皮癌に対する小骨頭放射線治療＋イメージガイドブ
ラキセラピーに関するレトロスペクティブスタディについての論文
Yoshimoto Y, Murata K, Irie D, Ando K, Adachi A, Aoki H, Hirakawa T, Noda
SE, Nakano T, Ohno T
A retrospective study of small-pelvis radiotherapy plus image-guided
brachytherapy in stage I-II non-bulky cervical squamous cell carcinoma
J Radiat Res. 2022 MAR 17;63(2):290-295.
Journal Impact Factor 2021: 2.438

PMID: 35152292 DOI: 10.1093/jrr/rrac001 WoS: WOS:000764165700001#消化器病学 #肝臓学

肝細胞癌に対する atezolizumab-bevacizumab 治療後に急速に進行した食道静脈
瘤の 2 症例についての論文
Furusawa A, Naganuma A, Suzuki Y, Hoshino T, Yasuoka H, Tamura
Y, Naruse H, Hatanaka T, Kakizaki S
Two cases of rapid progression of esophageal varices after
atezolizumab-bevacizumab treatment for hepatocellular carcinoma
Clin J Gastroenterol. 2022 APR;15(2):451-459.
Journal Impact Factor 2021: N/A

PMID: 35179703 DOI: 10.1007/s12328-022-016059 WoS: WOS:000757779100001#細胞生物学

特発性肺線維症患者における Pirfenidone と Nintedanib の投与中止プロファイルの差異についての論文
Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y, Yoshimi S,
Yatomi M, Shin Y, Wakamatsu I, Umetsu K, Kouno S, Nakagawa J, Sunaga
N, Maeno T, Hisada T

Differential Discontinuation Profiles between Pirfenidone and Nintedanib
in Patients with Idiopathic Pulmonary Fibrosis
Cells. 2022 JAN;11(1)Journal Impact Factor 2021: 7.666

PMID: 35011705 DOI: 10.3390/cells11010143 WoS: WOS:000758387000001#消化器病学 #肝臓学

進行性肝細胞癌に対するアテゾリズマブ＋ベバシズマブの有効性と早期ベバシズマブ
中断の関連性：ランドマーク分析についての論文
Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Kakizaki S, Shimada N, Kawata
K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N,
Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K,
Iijima H, Hiasa Y, Kumada T, Real-life Practice Experts HCC REL, HCC 48 Grp
Association of early bevacizumab interruption with efficacy of
atezolizumab plus bevacizumab for advanced hepatocellular carcinoma:
A landmark analysis
Hepatol Res. 2022 MAY;52(5):462-470.
Journal Impact Factor 2021: 4.942

PMID: 35080087 DOI: 10.1111/hepr.13748 WoS: WOS:000753243900001#腫瘍学 #多施設共同研究

高度に前治療された転移性胃がんに対するニボルマブ治療患者における潜在的な予後因子としての臨床的特徴：多施設共同レトロスペクティブスタディについての論文
Sano A, Sohda M, Nakazawa N, Ubukata Y, Kuriyama K, Kimura A, Kogure N,
Hosaka H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sakai M, Ogawa H,
Shirabe K, Saeki H
Clinical features as potential prognostic factors in patients treated withnivolumab for highly pretreated metastatic gastric cancer: a multicenter
retrospective study
BMC Cancer. 2022 JAN 3;22(1)Journal Impact Factor 2021: 4.638

PMID: 34980017 DOI: 10.1186/s12885-021-091183 WoS: WOS:000738001600006